Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Amateur Traders Corner -- Ignore unavailable to you. Want to Upgrade?

To: jjs_ynot who wrote (662)	9/1/2000 2:27:09 PM
From: Tom Hua	Read Replies (3) \| Respond to of 19633

Dave, I'm buying SNAP in the low 6s. This biotech undiscovered gem has a very broad portfolio of intellectual property with over 100 patents. SNAP will be presenting at the Bear Stearns Biotech Conference on Sept 13. In addition, several of its scientists will be making presentations at 2 upcoming scientific conferences: Society of Neuro-Sciences early November, ACNT early December. Below is a brief bio of the company. Synaptic Pharmaceutical Corporation ("Synaptic" or the "Company") is a biotechnology company engaged in the development of a broad platform of enabling technology which it calls "human receptor-targeted drug design technology." The Company is utilizing this technology in its genomics program to discover and clone the genes that code for human receptors. The Company and its licensees are also utilizing this technology in functional genomics programs to discover the function of these receptors in the body and thus specific physiological disorders with which they may be associated. The Company and its licensees are in turn utilizing the cloned receptor genes to design compounds that can potentially be developed as drugs for treating these disorders. Regards, Tom